Patent Assignment
Reel/Frame 031414/0660
Short-Form Patent Security Agreement
Recorded: 2013-10-15
Pages: 19
Assignor
EXAGEN DIAGNOSTICS, INC.
Executed: 2013-10-10
Assignees
CAPITAL ROYALTY PARTNERS II L.P.
1000 MAIN STREET, SUITE 2500, HOUSTON, TEXAS, 77002
CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.
1000 MAIN STREET, SUITE 2500, HOUSTON, TEXAS, 77002
PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
1000 MAIN STREET, SUITE 2500, HOUSTON, TEXAS, 77002
Covered Properties
(25)
Methods and Devices Relating to Estimating Classifier Performance
Methods of Quantifying Methotrexate Metabolites
Methods for Direct Detection of Individual Methotrexate Metabolites
Diagnosis and Monitoring of Systemic Lupus Erythematosus and of Scleroderma
Diagnosing and Monitoring Inflammatory Diseases by Measuring Complement Components on White Blood Cells
Identification and Monitoring of Systemic Lupus Erythematosus
Monitoring Immunologic, Hematologic and Inflammatory Diseases
Methods for Optimizing Clinical Responsiveness to Methotrexate Therapy Using Metabolite Profiling and Pharmacogenetics
Compositions for Glioma Classification
Real Time Method of Detecting Acute Inflammatory Conditions
Methods for Predicting Methotrexate Polyglutamate Levels Using Pharmacogenetics
Acute Myelogenous Leukemia Biomarkers
Methods of Predicting Methotrexate Efficacy and Toxicity
Application:
12/194,501 →
Publication:
US 2010/0203507
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Methods and Devices Relating to Estimating Classifier Performance
Identification and Monitoring of Systemic Lupus Erythematosus
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Biomarkers for Inflammatory Bowel Disease and Irritable Bowel Syndrome
Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants
Application:
13/756,616 →
Publication:
US 2013/0216530
Methods for Monitoring Methotrexate Therapy
Methods for Diagnosing Systemic Lupus Erythematosus
Methods For Treating and Diagnosing Systemic Lupus Erythematosus
Application:
61/792,284 →
Related Assignments
(15)
Other recorded transfers of the patents in this record — the chain of ownership.
Release of Security Interest
Dec 29, 2015
From: BANK OF AMERICA, N.A.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 037378/0464 →
Release of Security Interest
Sep 1, 2017
From: CYPRESS BIOSCIENCE INC.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043747/0382 →
Release of Security Interest
Sep 7, 2017
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: EXAGEN DIAGNOSTICS, INC.
Reel/Frame 043784/0828 →
Security Interest
Sep 11, 2017
From: EXAGEN DIAGNOSTICS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 043548/0228 →
Merger
Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
Corrective Assignment to Correct the English Translation to Show the Full and Correct New Name in Section 51. Previously Recorded at Reel: 049391 Frame: 0756. Assignor(S) Hereby Confirms the Merger.
Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
Assignment of Assignor's Interest
Aug 26, 2019
From: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
To: PRECISION IBD, INC.
Reel/Frame 050166/0001 →
Change of Name
Oct 17, 2019
From: PRECISION IBD, INC.
To: PROMETHEUS BIOSCIENCES, INC.
Reel/Frame 050886/0942 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912.
Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
Corrective Assignment to Correct the Patent Number 16062921 Previously Recorded on Reel 049391 Frame 0756. Assignor(S) Hereby Confirms the Patent Number Should Have Been 16062912.
Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
Assignment of Assignor's Interest
Oct 7, 2021
From: PROMETHEUS BIOSCIENCES, INC.
To: PROMETHEUS LABORATORIES INC.
Reel/Frame 057730/0993 →
Assignment of Assignor's Interest
Nov 3, 2021
From: PROMETHEUS LABORATORIES INC.
To: EXAGEN INC.
Reel/Frame 058007/0978 →
Security Interest
Apr 25, 2025
From: EXAGEN INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 070952/0802 →
Release of Security Interest
Apr 25, 2025
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: EXAGEN INC.
Reel/Frame 070951/0040 →
Release of Security Interest
Sep 4, 2025
From: NEW MEXICO MEZZANINE PARTERSN, L.P.; NEW MEXICO CO-INVESTMENT FUND, L.P.
To: EXAGEN INC.
Reel/Frame 072159/0497 →